Biopharmaceutical company Dimerix (ASX:DXB) confirmed that the fifth Independent Data Monitoring Committee (IDMC) review of the Action3 phase 3 trial data identified no safety concerns and recommended the trial's continuation, according to a Wednesday filing with the Australian bourse.
The study is evaluating the efficacy and safety of the company's product candidate DMX200 in patients with focal segmental glomerulosclerosis kidney disease, the filing said.
The next IDMC meeting is scheduled for the second quarter of 2025, according to the filing.
Dimerix shares fell nearly 3% in afternoon trade Thursday.
Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.99%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.